Chapter 20: Neuromuscular Blocking Drugs — Module 1: Neuromuscular Junction Physiology and the Pharmacological Basis of Blockade Tier 3 — Clinical Vignette (11 questions)
1. A 38-year-old man sustained full-thickness burns to 45% of his body surface area in a house fire approximately 48 hours ago. He is intubated and sedated in the burn ICU. He requires reintubation for a planned airway exchange procedure, and the team is selecting a neuromuscular blocking agent. A junior resident suggests succinylcholine for rapid sequence intubation given its fast onset and short duration. Which of the following is the most appropriate response to this suggestion?
A) Succinylcholine is safe in this patient because 48 hours is too early for clinically significant extrajunctional receptor upregulation — that process requires at least 7 to 10 days; proceed with the standard intubating dose of succinylcholine 1.5 mg/kg
B) Succinylcholine is contraindicated in this patient because extrajunctional gamma-subunit nAChR upregulation begins within approximately 24 to 48 hours of burn injury and is already underway; succinylcholine depolarization of the expanded extrajunctional receptor surface produces aggregate potassium efflux that can raise serum potassium to life-threatening levels; rocuronium is the appropriate alternative for rapid sequence intubation
C) Succinylcholine is safe in this patient because the burn area must exceed 60% of body surface area before extrajunctional receptor upregulation reaches the threshold required for dangerous hyperkalemia; at 45% BSA, the aggregate potassium release from extrajunctional receptors remains within the normal physiological range
D) Succinylcholine is appropriate in this patient because the hyperkalemia risk applies only to electrical burns, not thermal burns; thermal injury does not trigger the denervation-like signaling that drives extrajunctional nAChR upregulation, and thermal burn patients can safely receive succinylcholine throughout their hospitalization
E) Succinylcholine is contraindicated in this patient, but only because of the risk of masseter spasm and malignant hyperthermia in burn patients — the potassium efflux mechanism does not apply because burned muscle is electrically inexcitable and cannot generate potassium efflux in response to depolarizing agents
ANSWER: B
Rationale:
This question asked you to apply the time course of extrajunctional receptor upregulation to a burn patient at 48 hours and determine whether succinylcholine is safe. Extrajunctional gamma-subunit nAChR upregulation begins within approximately 24 to 48 hours of the triggering condition — burn injury, denervation, prolonged immobilization, or critical illness. At 48 hours post-burn, this patient already has significant extrajunctional receptor proliferation underway across the muscle membrane surface. These gamma-subunit receptors have a mean channel open time of approximately 6 milliseconds compared to less than 1 millisecond for the adult epsilon-subunit receptors at the normal junctional area. Succinylcholine depolarization of this vastly expanded receptor surface produces aggregate potassium efflux sufficient to cause dangerous hyperkalemia and ventricular fibrillation. The contraindication applies from approximately 24 to 48 hours post-injury and persists for months. Rocuronium at an appropriate intubating dose (1.2 mg/kg for rapid sequence intubation) is the correct alternative.
Option A: Option A is incorrect because the 7 to 10 day threshold substantially underestimates the onset time — extrajunctional upregulation begins within 24 to 48 hours, meaning this patient is already at risk; waiting for the stated 7 to 10 days before considering the contraindication would expose patients to the hyperkalemia risk during this critical early window.
Option C: Option C is incorrect because no 60% BSA threshold exists for the succinylcholine hyperkalemia contraindication — the contraindication applies to burns of all significant extents, and 45% BSA full-thickness burns represent extensive injury more than sufficient to drive extrajunctional receptor upregulation; no body surface area percentage below which the risk is absent has been established.
Option D: Option D is incorrect because thermal burns absolutely trigger extrajunctional receptor upregulation — the mechanism involves loss of neural trophic influence, disuse, and direct muscle injury, all of which are present in thermal burns; the hyperkalemia risk from succinylcholine in burn patients was first described in thermal burn patients and is not restricted to electrical injury.
Option E: Option E is incorrect because masseter spasm and malignant hyperthermia are not the primary contraindication to succinylcholine in burn patients, and the mechanism stated is pharmacologically incorrect — burned muscle retains the ability to be depolarized by succinylcholine at extrajunctional receptors; the potassium efflux mechanism is real and is the established basis for the contraindication.
2. A 67-year-old man with ventilator-associated pneumonia is receiving tobramycin and a vecuronium infusion for ventilator synchrony in the medical ICU. The nursing staff notes that his TOF count has been zero for the past 6 hours despite a vecuronium infusion rate that typically produces moderate block (TOF count 1 to 2) in other patients. Renal function is normal and vecuronium plasma levels are within the expected range. Which of the following best explains the unexpectedly deep block and guides appropriate management?
A) Tobramycin competitively inhibits acetylcholinesterase in the synaptic cleft, causing ACh accumulation that produces persistent end-plate depolarization similar to Phase II succinylcholine block; the management is to stop vecuronium and administer sugammadex, which will chelate tobramycin as well as the steroidal NMBD
B) Tobramycin has displaced vecuronium from plasma protein binding sites, increasing free vecuronium concentration and effectively doubling its pharmacodynamic potency; management requires reducing the vecuronium infusion rate by 50% and monitoring for spontaneous recovery of protein binding equilibrium over the next 12 to 24 hours
C) Tobramycin inhibits hepatic CYP3A4 enzymes responsible for vecuronium deacetylation, slowing its elimination and producing accumulation to supratherapeutic concentrations; the management is to reduce the vecuronium dose and monitor liver function tests to assess when CYP activity recovers
D) Tobramycin has a direct postsynaptic effect at the nAChR, acting as a competitive antagonist at the alpha-1 binding site and adding to vecuronium's competitive block; standard neostigmine reversal cannot overcome the combined block because it must displace both tobramycin and vecuronium simultaneously from the receptor
E) Tobramycin inhibits presynaptic voltage-gated calcium channels (Cav2.1), reducing ACh quantal release per nerve impulse; this presynaptic ACh deficit amplifies vecuronium's competitive block at the nAChR by shifting the ACh/vecuronium ratio further in favor of the drug; management requires reducing the vecuronium infusion rate, anticipating prolonged block duration, and using quantitative TOF monitoring to guide any reversal rather than relying on standard dose schedules
ANSWER: E
Rationale:
This question asked you to identify the mechanism by which an aminoglycoside antibiotic potentiates non-depolarizing neuromuscular block and derive the management approach. Aminoglycosides including tobramycin inhibit presynaptic voltage-gated calcium channel (Cav2.1) function, reducing calcium influx per nerve impulse and decreasing ACh quantal release. The degree of competitive block at the nAChR at any moment depends on the ratio of vecuronium concentration to ACh concentration at the receptor. When tobramycin reduces ACh release, this ratio shifts further in favor of vecuronium even without any change in vecuronium plasma concentration — amplifying the block to a depth greater than vecuronium alone would produce. Because plasma vecuronium levels are within the expected range in this patient, the unexpectedly deep block is explained by tobramycin's presynaptic amplification rather than vecuronium accumulation. Management requires recognizing the interaction, reducing the vecuronium infusion rate, anticipating prolonged block duration, and using quantitative TOF monitoring — standard vecuronium dose schedules and reversal criteria cannot be applied because the combined presynaptic plus postsynaptic block is deeper and less predictable than vecuronium-only block.
Option A: Option A is incorrect because tobramycin does not inhibit AChE — aminoglycosides act presynaptically on Cav2.1 calcium channels, not on synaptic AChE; and sugammadex is a selective binding agent for steroidal NMBDs (rocuronium, vecuronium) that does not chelate aminoglycoside antibiotics.
Option B: Option B is incorrect because tobramycin does not displace vecuronium from plasma protein binding — vecuronium is minimally protein-bound and this pharmacokinetic mechanism does not explain the interaction; the amplification is pharmacodynamic at the NMJ, not a protein-binding displacement.
Option C: Option C is incorrect because vecuronium is not metabolized by CYP3A4 — it undergoes hepatic deacetylation and biliary excretion; aminoglycosides are renally cleared without CYP involvement and no CYP-based interaction between these drugs is established.
Option D: Option D is incorrect because tobramycin does not act as a postsynaptic competitive antagonist at the nAChR alpha-1 binding site — the primary mechanism of aminoglycoside potentiation of NMB is presynaptic calcium channel inhibition, not postsynaptic receptor competition; and neostigmine can provide partial reversal of the combined block, though it may be incomplete because it cannot restore presynaptic calcium channel function.
3. A 29-year-old woman with myasthenia gravis is recovering in the post-anesthesia care unit following an uncomplicated thymectomy under general anesthesia. She received cisatracurium 0.15 mg/kg (standard intubating dose) for intubation approximately 90 minutes ago. She remains weak with a TOF count of 1 and is unable to sustain head lift. Her anesthesiologist is not surprised. Which of the following best explains why this patient's neuromuscular block is still profound at a time when it would typically be fully resolved in a patient without myasthenia gravis?
A) In myasthenia gravis, autoantibodies against junctional nAChRs reduce functional receptor number and erode the NMJ margin of safety; because the safety margin is already compromised at baseline, a non-depolarizing NMBD requires far fewer receptors to be blocked before the EPP falls below Nav1.4 threshold — producing a block that is disproportionately deep and prolonged for the dose administered, even after significant spontaneous recovery of drug plasma concentration
B) In myasthenia gravis, autoantibodies inhibit the hepatic enzymes responsible for cisatracurium metabolism, slowing its breakdown via Hofmann elimination and causing plasma drug levels to remain elevated long after a standard intubating dose; the prolonged block is therefore pharmacokinetic rather than pharmacodynamic in origin
C) In myasthenia gravis, upregulation of extrajunctional gamma-subunit nAChRs across the muscle membrane provides additional receptor targets for cisatracurium that must all be occupied before recovery can begin; the expanded receptor surface prolongs block duration by requiring more extensive drug dissociation before adequate transmission resumes
D) In myasthenia gravis, the autoantibodies directly bind and stabilize cisatracurium at the nAChR alpha-1 subunit, slowing its dissociation from the receptor; this immune-mediated stabilization of drug-receptor complexes produces a pharmacodynamic prolongation that cannot be reversed by neostigmine or sugammadex
E) In myasthenia gravis, the thymus produces a factor that sensitizes nAChRs to competitive antagonism by non-depolarizing NMBDs; following thymectomy, this sensitizing factor is still present in the circulation for 3 to 6 months, explaining why MG patients remain unusually sensitive to NMBDs in the immediate post-thymectomy period
ANSWER: A
Rationale:
This question asked you to apply the pharmacodynamic consequences of reduced nAChR number in MG to explain disproportionately prolonged non-depolarizing block. In MG, autoantibodies against the alpha-1 subunit of the junctional nAChR reduce functional receptor number through blocking, crosslinking, and complement-mediated destruction. The reduced receptor density shrinks the EPP safety margin — the buffer between normal EPP amplitude and the Nav1.4 activation threshold. When this safety margin is already narrowed at baseline, a non-depolarizing NMBD requires far fewer additional receptors to be blocked before the EPP falls below the threshold needed to trigger a muscle action potential. At the standard intubating dose of cisatracurium, enough receptor occupancy is achieved to produce profound block that persists long after the same dose would have resolved in a patient with a full receptor complement. Importantly, even as plasma cisatracurium concentration falls and receptor occupancy decreases with spontaneous recovery, each percentage point of remaining receptor block has a larger clinical impact in MG because there is no safety margin to absorb it. This is why MG patients are managed with the minimum effective NMBD dose and require quantitative monitoring to guide reversal.
Option B: Option B is incorrect because cisatracurium undergoes Hofmann elimination — a non-enzymatic spontaneous degradation process that occurs at physiological pH and temperature — not hepatic enzyme-mediated metabolism; MG autoantibodies have no effect on Hofmann elimination kinetics, and the prolonged block is pharmacodynamic, not pharmacokinetic.
Option C: Option C is incorrect because MG does not drive extrajunctional gamma-subunit nAChR upregulation — extrajunctional upregulation is associated with denervation, burns, immobilization, and critical illness; in MG the primary effect is junctional receptor reduction, not extrajunctional proliferation, and the extended receptor surface mechanism does not apply.
Option D: Option D is incorrect because no mechanism exists by which MG autoantibodies stabilize NMBD-receptor complexes — autoantibodies target the nAChR protein, not the drug-receptor interaction; cisatracurium binds non-covalently to the receptor through normal competitive antagonism, and its dissociation kinetics are determined by pharmacokinetics, not immune stabilization.
Option E: Option E is incorrect because the thymus in MG produces autoantibodies against the nAChR, not a separate NMB-sensitizing factor; thymectomy reduces autoantibody production over time, but no thymus-derived NMB-sensitizing circulating factor distinct from anti-nAChR antibodies is an established component of MG pathophysiology.
4. A 26-year-old woman at 35 weeks gestation with severe preeclampsia is receiving intravenous magnesium sulfate 2 g/hour for seizure prophylaxis. Her blood pressure deteriorates and she is scheduled for emergency cesarean delivery under general anesthesia. The anesthesiologist plans to use rocuronium for rapid sequence intubation and wants to avoid both inadequate intubating conditions and prolonged postoperative residual block. Which of the following best describes the appropriate modification to rocuronium management in this patient?
A) No modification to rocuronium dosing is necessary because magnesium sulfate at the standard obstetric dose does not produce clinically significant interactions with non-depolarizing NMBDs; the pharmacodynamic interaction between magnesium and rocuronium is only relevant at magnesium levels above the therapeutic range for eclampsia prophylaxis
B) The rocuronium dose should be increased to 1.6 mg/kg rather than the standard 1.2 mg/kg for rapid sequence intubation because magnesium antagonizes rocuronium at the nAChR by competing for the same binding site, reducing its potency and requiring a higher dose to achieve intubating conditions within 60 seconds
C) The rocuronium dose should be reduced below standard rapid sequence intubation dosing — titrated carefully with the expectation that onset may be faster and block deeper and more prolonged than in non-magnesium-treated patients — and quantitative TOF monitoring must be used to guide reversal timing because standard recovery criteria and reversal schedules cannot be reliably applied in the presence of therapeutic magnesium
D) Rocuronium is contraindicated in this patient because magnesium and rocuronium together produce an irreversible block at the nAChR that cannot be reversed by neostigmine or sugammadex; succinylcholine should be used instead because its depolarizing mechanism is unaffected by presynaptic magnesium effects
E) Sugammadex should be prepared at the standard 16 mg/kg dose for immediate reversal if needed, but rocuronium dosing does not require modification because sugammadex will reliably encapsulate and remove all rocuronium regardless of how magnesium has altered the depth or duration of block
ANSWER: C
Rationale:
This question asked you to apply the magnesium-NMBD interaction to perioperative management in a preeclamptic patient. Magnesium inhibits presynaptic Cav2.1 calcium channels, reducing ACh quantal release per nerve impulse. This reduction in synaptic ACh amplifies rocuronium's competitive block — the ACh/rocuronium ratio at the nAChR shifts further in favor of the drug — producing deeper block at a given rocuronium dose and prolonging duration of effect. In this patient, the correct approach is to reduce the rocuronium dose below the standard rapid sequence dose, with the understanding that onset may be faster and block more profound than expected. Quantitative TOF monitoring at the adductor pollicis is essential because standard recovery timelines and reversal dose schedules based on non-magnesium patients cannot be reliably applied; the presynaptic ACh deficit persists as long as magnesium levels are therapeutic, and objective monitoring is the only way to confirm adequate recovery before extubation.
Option A: Option A is incorrect because magnesium at standard obstetric doses does produce clinically significant potentiation of non-depolarizing NMBDs — this interaction is well-established and clinically important; the threshold for interaction is not above the therapeutic range, making this assertion dangerous if acted upon.
Option B: Option B is incorrect because magnesium does not antagonize rocuronium at the nAChR by competing for the binding site — magnesium acts presynaptically on Cav2.1 calcium channels; because it reduces ACh release, it amplifies rather than antagonizes the competitive block of rocuronium, and the dose should be reduced rather than increased.
Option D: Option D is incorrect because the magnesium-rocuronium block is not irreversible — it is a pharmacodynamic potentiation of reversible competitive antagonism; both neostigmine and sugammadex can reverse the rocuronium component, though reversal may be less complete if magnesium-mediated presynaptic ACh deficit persists; rocuronium is not contraindicated in this scenario.
Option E: Option E is incorrect because while sugammadex is an appropriate rescue agent for rocuronium reversal, the dose of 16 mg/kg is specifically for immediate reversal of a full intubating dose — the claim that rocuronium dosing requires no modification contradicts the established pharmacodynamic interaction and could result in unexpectedly deep and prolonged block.
5. A 44-year-old woman received succinylcholine 1.5 mg/kg for rapid sequence intubation at the start of a laparoscopic cholecystectomy. The procedure lasted 45 minutes. At the end of the case, she remains fully paralyzed with a TOF count of zero and shows no spontaneous respiratory effort. TOF monitoring confirms no fade — all four twitches are equally absent. The anesthesiologist suspects pseudocholinesterase deficiency. A colleague suggests giving neostigmine to speed recovery. Which of the following is the most appropriate response?
A) Give neostigmine 0.05 mg/kg with glycopyrrolate immediately, as neostigmine reverses prolonged succinylcholine block by inhibiting AChE and allowing ACh to accumulate; the same mechanism that reverses non-depolarizing block will accelerate recovery from pseudocholinesterase-deficient succinylcholine block because both involve receptor occupancy that can be overcome by elevated ACh
B) Give neostigmine only after confirming the TOF count has returned to 4, because neostigmine is ineffective when TOF count is zero regardless of the cause of block; once 4 twitches are present, neostigmine can be given to accelerate final recovery from the succinylcholine block
C) Give sugammadex 16 mg/kg, as it will encapsulate and remove succinylcholine from the circulation just as it does rocuronium, reversing the block regardless of the mechanism of prolongation
D) Do not give neostigmine — this patient is in Phase I depolarizing block; neostigmine inhibits AChE, causing ACh to accumulate at persistently depolarized end-plates and worsening the block; the correct management is to continue mechanical ventilation and allow succinylcholine to dissipate from the synapse spontaneously as plasma pseudocholinesterase slowly hydrolyzes the drug
E) Give fresh frozen plasma immediately to replenish pseudocholinesterase activity; transfused pseudocholinesterase will hydrolyze the remaining succinylcholine within minutes, producing rapid recovery without requiring any pharmacological reversal agents
ANSWER: D
Rationale:
This question asked you to apply understanding of Phase I block and the mechanism of neostigmine to manage prolonged succinylcholine block from pseudocholinesterase deficiency. The TOF pattern — equal absence of all four twitches with no fade — identifies this as Phase I depolarizing block. In Phase I block, the end-plate is persistently depolarized by succinylcholine occupying and activating nAChRs. Neostigmine inhibits AChE, causing ACh to accumulate at these already-depolarized end-plates. Rather than reversing the block, increased ACh adds further agonist drive to persistently depolarized receptors — maintaining or deepening the block. Neostigmine is therefore contraindicated in Phase I succinylcholine block. The correct management is to continue mechanical ventilation and allow succinylcholine to dissipate naturally. Although plasma pseudocholinesterase activity is reduced in this patient, the drug will eventually diffuse away from the synapse and be hydrolyzed at whatever rate the abnormal enzyme permits — block will resolve spontaneously, typically over 2 to 4 hours in homozygous atypical cases. The patient should be kept sedated and ventilated during this period.
Option A: Option A is incorrect because neostigmine does not reverse Phase I succinylcholine block — the mechanism stated (ACh accumulation overcoming receptor occupancy) is valid for non-depolarizing competitive antagonists, but succinylcholine is a depolarizing agonist and increasing ACh at an already-depolarized end-plate worsens rather than reverses the block.
Option B: Option B is incorrect because neostigmine should not be given even when TOF count returns to 4 in this scenario — a return of 4 twitches in Phase I block still means all twitches are equally reduced with no fade, and giving neostigmine at this point would add ACh to still-depolarized receptors; neostigmine is harmful in Phase I block regardless of TOF count.
Option C: Option C is incorrect because sugammadex is a selective binding agent that encapsulates steroidal NMBDs — specifically rocuronium and vecuronium — through a molecular cage mechanism; it has no binding affinity for succinylcholine, which is a short, flexible bis-choline ester structurally incompatible with the sugammadex cavity.
Option E: Option E is incorrect because fresh frozen plasma is not a reliable or timely treatment for pseudocholinesterase deficiency — the amount of pseudocholinesterase delivered by fresh frozen plasma is insufficient to meaningfully accelerate succinylcholine hydrolysis, and the approach carries unnecessary risks of transfusion reactions, volume overload, and infection; the established management is supportive ventilation.
6. A 57-year-old man with a 3-month history of proximal limb weakness and a recently confirmed diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) associated with small cell lung cancer requires flexible bronchoscopy with moderate sedation. The pulmonologist asks whether a small dose of a neuromuscular blocking drug could be used for vocal cord relaxation if needed. Which of the following most accurately characterizes the expected pharmacological response to both depolarizing and non-depolarizing NMBDs in this patient and guides appropriate drug selection?
A) LEMS patients are resistant to non-depolarizing NMBDs because their reduced ACh release means less competition for the binding sites, allowing more drug to reach unoccupied receptors and produce faster onset; however, they are sensitive to succinylcholine because fewer competing ACh molecules are present to prevent the depolarizing agent from maintaining persistent receptor occupancy
B) LEMS patients are sensitive to both non-depolarizing and depolarizing NMBDs because autoantibodies against presynaptic Cav2.1 channels reduce ACh quantal release, eroding the NMJ margin of safety; a non-depolarizing agent needs to block fewer postsynaptic receptors to eliminate the already-diminished EPP, and succinylcholine depolarizes a junction already operating with reduced presynaptic reserve; if an NMBD is needed, the lowest possible dose of a short-acting non-depolarizing agent with quantitative monitoring is the safest approach
C) LEMS patients are sensitive to non-depolarizing NMBDs and resistant to succinylcholine, identical to the pattern seen in myasthenia gravis; the two conditions produce the same NMBD sensitivity profile because both reduce functional nAChR availability, and clinical management is therefore identical for both diseases
D) LEMS patients have normal sensitivity to both NMBD classes because the autoantibody effect on Cav2.1 channels is fully compensated by post-tetanic facilitation — repetitive nerve stimulation in the clinical context produces sufficient calcium accumulation to restore normal quantal release and re-establish the full NMJ safety margin before drug administration
E) LEMS patients are resistant to both non-depolarizing and depolarizing NMBDs because reduced ACh release from Cav2.1 dysfunction causes upregulation of postsynaptic nAChRs as a compensatory response; the upregulated receptor population provides a larger target for both drug classes, effectively diluting the block and requiring higher doses than in healthy patients
ANSWER: B
Rationale:
This question asked you to apply the LEMS pathophysiology to predict NMBD sensitivity and select the appropriate management approach. In LEMS, autoantibodies against Cav2.1 (P/Q-type) voltage-gated calcium channels at the presynaptic active zone reduce calcium influx per nerve impulse, decreasing ACh quantal release. The NMJ safety margin depends on ACh release exceeding the threshold needed to generate a suprathreshold EPP by a factor of 3 to 4. When quantal release is reduced by LEMS, this buffer is narrowed, and the junction operates closer to its transmission limit. For non-depolarizing NMBDs: fewer postsynaptic receptors need to be blocked before the already-diminished EPP falls below Nav1.4 threshold — producing disproportionately deep block. For succinylcholine: the junction is already operating with reduced safety margin, making persistent depolarization easier to establish and less resistance. Both classes are enhanced because the underlying deficit is presynaptic quantal release failure — a fundamentally different mechanism from MG, where postsynaptic receptor loss produces opposite sensitivity profiles for the two classes. The safest approach is the lowest possible dose of a short-acting non-depolarizing agent with careful quantitative monitoring.
Option A: Option A is incorrect because it inverts the non-depolarizing NMBD sensitivity — LEMS patients are sensitive to (not resistant to) non-depolarizing agents; and the stated reasoning that reduced ACh competition produces faster onset is mechanistically confused — reduced ACh shifts the competitive equilibrium toward the drug, amplifying rather than simply accelerating the block.
Option C: Option C is incorrect because LEMS and MG produce opposite sensitivity profiles for succinylcholine — MG patients are relatively resistant to succinylcholine (fewer functional junctional receptors available for agonist depolarization) while LEMS patients are sensitive to succinylcholine (reduced safety margin); conflating the two diseases' sensitivity profiles is a clinically dangerous error.
Option D: Option D is incorrect because post-tetanic facilitation in LEMS does produce transient improvement in neuromuscular transmission during repetitive stimulation, but this effect does not fully restore normal quantal release to the sustained level needed to re-establish a full safety margin before drug administration; the Cav2.1 deficit persists as long as the autoantibodies are present.
Option E: Option E is incorrect because reduced ACh release from presynaptic Cav2.1 dysfunction does not trigger compensatory upregulation of postsynaptic nAChRs — receptor upregulation is associated with denervation, disuse, and direct muscle injury; LEMS is a presynaptic disorder and compensatory postsynaptic receptor upregulation is not an established feature.
7. A 55-year-old man undergoes an elective laparoscopic Nissen fundoplication under general anesthesia with rocuronium for neuromuscular relaxation. At the end of the procedure, the anesthesiologist applies nerve stimulation to the facial nerve and observes a TOF ratio of 1.0 at the orbicularis oculi. Satisfied that recovery is complete, she extubates the patient. In the recovery room, the patient develops partial upper airway obstruction, is unable to swallow secretions effectively, and requires reintubation. A root cause analysis is performed. Which of the following best identifies the monitoring error that led to this outcome?
A) The anesthesiologist used the wrong stimulation frequency — TOF should be applied at 1 Hz rather than 2 Hz; at 2 Hz, individual twitches are too close together to allow complete mechanical recovery between stimuli, causing artificial underestimation of the TOF ratio and a false appearance of complete recovery
B) The anesthesiologist failed to confirm a TOF ratio of at least 1.0 at both the facial nerve and the ulnar nerve simultaneously; current guidelines require dual-site confirmation before extubation, and a TOF ratio of 1.0 at the facial nerve alone is insufficient without a matching result at the adductor pollicis
C) The anesthesiologist used qualitative rather than quantitative assessment — subjective visual assessment of the orbicularis oculi TOF response cannot reliably detect fade when the ratio is between 0.7 and 0.9; the patient likely had a TOF ratio of approximately 0.75 to 0.85 at the facial nerve, which appeared complete to visual inspection but was insufficient for safe extubation
D) The anesthesiologist applied supramaximal rather than submaximal stimulation — supramaximal stimulation activates additional motor units that are not blocked, artificially elevating the TOF ratio above its true value at physiological stimulation intensities; submaximal stimulation would have revealed the true residual block
E) The facial nerve (orbicularis oculi) recovers earlier than the adductor pollicis following non-depolarizing block; a TOF ratio of 1.0 at the facial nerve does not guarantee a TOF ratio of 0.9 at the adductor pollicis — the standard monitoring site; pharyngeal and upper airway protective muscles likely still had significant residual block at the time of extubation, explaining the inability to protect the airway despite apparent complete recovery at the facial nerve
ANSWER: E
Rationale:
This question asked you to identify the monitoring site selection error that caused post-extubation airway compromise. The facial nerve (monitoring the orbicularis oculi or corrugator supercilii) recovers earlier than the adductor pollicis following non-depolarizing neuromuscular block. This site-dependent difference in recovery kinetics means that a TOF ratio of 1.0 observed at the facial nerve does not guarantee a TOF ratio of 0.9 at the adductor pollicis — the ulnar nerve and adductor pollicis monitoring site is the established standard reference for confirming adequate recovery before extubation. In this patient, the TOF ratio at the adductor pollicis was likely still below 0.9 at the time of extubation despite the facial nerve showing complete recovery. Upper airway protective muscles — pharyngeal constrictors, laryngeal adductors, and hypopharyngeal muscles — recover later than the orbicularis oculi after non-depolarizing block and may retain clinically significant residual block even when the facial nerve appears fully recovered. The root cause is the choice of an inappropriate monitoring site that systematically overestimates recovery.
Option A: Option A is incorrect because TOF is correctly applied at 2 Hz — four stimuli at 2 Hz over 2 seconds is the established TOF protocol; using 1 Hz is not the standard and would not have produced the adverse outcome described; the stimulation frequency was not the error.
Option B: Option B is incorrect because current monitoring guidelines do not require simultaneous dual-site confirmation — the standard is quantitative monitoring at the adductor pollicis (ulnar nerve); dual-site monitoring is not the established requirement, and the error in this case was choosing the facial nerve as the sole monitoring site rather than the correct site.
Option C: Option C is incorrect because the scenario specifies a TOF ratio of 1.0 — not a value in the 0.75 to 0.85 range that might be missed by qualitative assessment; the problem is not qualitative versus quantitative assessment at the facial nerve, but that the facial nerve itself recovers earlier than the adductor pollicis; even a quantitatively confirmed TOF ratio of 1.0 at the facial nerve would not guarantee adequate recovery at the adductor pollicis.
Option D: Option D is incorrect because supramaximal stimulation is the correct technique for neuromuscular monitoring — it ensures that all motor fibers in the nerve are activated consistently, allowing reproducible comparisons of twitch amplitude; submaximal stimulation would introduce variability and is not the standard approach.
8. A 71-year-old man with severe acute respiratory distress syndrome in the medical ICU has been receiving a succinylcholine infusion at 3 mg/min for approximately 100 minutes to facilitate ventilator synchrony. The ICU nurse performing hourly TOF checks notes that the pattern has changed — previously the TOF showed equal absence or equal reduction of all four twitches, but now the fourth twitch is noticeably smaller than the first, and post-tetanic twitches are detectable after a tetanic stimulus. The intensivist asks what has happened and how to proceed. Which of the following most accurately explains the monitoring change and describes the most appropriate management?
A) The TOF pattern change — from equal twitch reduction without fade to progressive fade with post-tetanic facilitation — indicates transition from Phase I to Phase II block; the management is to stop the succinylcholine infusion, avoid giving neostigmine until the block character has been re-assessed (as neostigmine may partially reverse Phase II block but its effect is unpredictable), and continue mechanical ventilation with close quantitative monitoring while allowing the block to evolve
B) The TOF fade now present indicates that the patient has developed a non-depolarizing block caused by succinylcholine metabolites; succinylmonocholine accumulates during prolonged infusions and acts as a competitive antagonist at the nAChR; treatment is to give neostigmine immediately to reverse the accumulating competitive metabolite block
C) The appearance of TOF fade indicates that the succinylcholine infusion rate has become insufficient to maintain Phase I block — the patient is partially recovering and the fade reflects re-establishment of normal neuromuscular transmission rather than a new block type; the appropriate response is to increase the infusion rate to restore full Phase I block
D) The TOF fade indicates that the patient's plasma pseudocholinesterase has been upregulated in response to the prolonged succinylcholine infusion, causing faster drug metabolism and a shift toward partial recovery; the management is to add a non-depolarizing agent to the infusion to supplement the weakening succinylcholine block
E) The TOF pattern change reflects an artifact of prolonged nerve stimulation rather than a true change in block type; repetitive TOF stimulation over 100 minutes causes progressive depletion of the nerve's action potential reserve, producing apparent fade that is not pharmacological; the block type remains Phase I and no change in management is required
ANSWER: A
Rationale:
This question asked you to identify the Phase I to Phase II transition from monitoring data and describe appropriate management. The TOF pattern change described — from equal twitch reduction without fade to progressive fade (T4 smaller than T1) with detectable post-tetanic facilitation — is the defining monitoring signature of Phase II block. Phase II block develops during prolonged or high-dose succinylcholine administration and involves receptor desensitization (conversion of nAChRs to a high-affinity closed conformation) and open-channel block (succinylcholine molecules occluding the open pore). These mechanisms produce a TOF pattern that resembles non-depolarizing block despite the drug being a depolarizing agonist. The correct management has three components: stop the succinylcholine infusion to prevent further Phase II development; avoid blind neostigmine administration because Phase II block shows partial but unpredictable sensitivity to anticholinesterases — giving neostigmine without confirming block character risks worsening the paralysis if residual Phase I block is present; and continue mechanical ventilation with close quantitative monitoring, reassessing the TOF pattern before any reversal attempt.
Option B: Option B is incorrect because succinylmonocholine, the primary hydrolysis product, is a weaker neuromuscular agent with minimal competitive antagonist activity at clinically encountered concentrations — it does not accumulate to levels that produce the TOF pattern described; Phase II block is caused by receptor desensitization and open-channel block by succinylcholine itself, not by metabolite competitive antagonism.
Option C: Option C is incorrect because the TOF fade is not a sign of partial recovery from Phase I block — TOF fade is categorically absent in Phase I block; its appearance represents a qualitative change in block mechanism, not an insufficient drug level; increasing the infusion rate would worsen Phase II block by adding more succinylcholine to an already desensitized receptor population.
Option D: Option D is incorrect because plasma pseudocholinesterase is not upregulated in response to succinylcholine infusion on any clinically relevant timescale — enzyme induction does not occur within 100 minutes; and the described management of adding a non-depolarizing agent would produce additive block on top of Phase II succinylcholine block, deepening rather than managing the situation.
Option E: Option E is incorrect because the TOF fade described — progressive amplitude reduction across four twitches with post-tetanic facilitation — is a pharmacological phenomenon reflecting a change in the mechanism of block, not an artifact of prolonged electrode stimulation; nerve action potential reserve depletion from repetitive stimulation does not produce the specific pattern of T4 smaller than T1 with post-tetanic facilitation.
9. A 34-year-old intravenous drug user presents with 3 days of progressive descending flaccid paralysis, diplopia, dysarthria, and dysphagia. Blood cultures are pending. Wound botulism is strongly suspected. The patient is now developing respiratory failure. A medical student asks why neostigmine cannot be used to reverse the paralysis the same way it reverses non-depolarizing neuromuscular block, and what the correct treatment strategy is. Which of the following best answers both questions?
A) Neostigmine could theoretically reverse botulinum toxin paralysis because it works by increasing ACh at the synapse, but the doses required would produce intolerable systemic muscarinic toxicity (bradycardia, bronchospasm, excessive secretions) before adequate reversal could be achieved; the correct treatment is atropine pretreatment to block muscarinic side effects followed by high-dose neostigmine titrated to effect
B) Neostigmine cannot reverse botulinum toxin paralysis because the toxin directly destroys postsynaptic nAChRs, leaving no functional receptor for ACh to bind; the correct treatment is intravenous immunoglobulin to block the postsynaptic receptor destruction, which halts progression but does not reverse existing paralysis
C) Neostigmine cannot reverse botulinum toxin paralysis because the toxin cleaves presynaptic SNARE proteins, abolishing ACh vesicle exocytosis entirely; with no ACh being released into the synaptic cleft, AChE inhibition has no substrate to preserve and provides no reversal; the correct treatment is immediate antitoxin administration to neutralize unbound circulating toxin, supportive mechanical ventilation, and wound debridement — recovery requires sprouting of new nerve terminals with intact SNARE machinery over weeks to months
D) Neostigmine cannot reverse botulinum toxin paralysis because the toxin permanently alkylates AChE in the synaptic cleft, eliminating the enzyme target that neostigmine requires for its mechanism; with no AChE present, ACh cannot accumulate regardless of how much neostigmine is given; the correct treatment is recombinant AChE replacement therapy combined with antitoxin
E) Neostigmine is partially effective in botulinum toxin paralysis and should be given empirically at maximum dose (0.1 mg/kg) while antitoxin is prepared; although it cannot fully reverse established paralysis, it may slow progression by reducing the rate at which the toxin gains access to presynaptic terminals via its ability to competitively inhibit the toxin's neuronal binding proteins
ANSWER: C
Rationale:
This question asked you to explain why neostigmine cannot reverse botulinum toxin paralysis and describe the correct management strategy. Botulinum toxin is taken up into the presynaptic motor nerve terminal and cleaves SNARE proteins — specifically VAMP/synaptobrevin, SNAP-25, or syntaxin depending on the serotype — which are required for synaptic vesicle fusion with the presynaptic membrane. Without functional SNARE proteins, ACh-filled vesicles cannot fuse with the membrane and no ACh is released into the synaptic cleft, regardless of how many nerve impulses arrive. Neostigmine inhibits AChE, which preserves ACh from hydrolysis after it is released — but if no ACh is released into the cleft in the first place, there is nothing to preserve. No amount of AChE inhibition can reverse a block where the fundamental problem is absent presynaptic transmitter release. The correct management includes antitoxin administration to neutralize unbound toxin in the circulation (preventing further nerve terminal uptake), wound debridement to eliminate the toxin source, supportive mechanical ventilation, and intensive care until new nerve terminal sprouts with intact SNARE machinery regenerate — a process taking weeks to months.
Option A: Option A is incorrect because the limitation of neostigmine in botulism is not a dose-limiting muscarinic toxicity problem — it is the complete absence of ACh release that makes neostigmine pharmacologically futile regardless of dose; muscarinic pretreatment with atropine cannot overcome the fundamental presynaptic deficit.
Option B: Option B is incorrect because botulinum toxin acts presynaptically on SNARE proteins inside the nerve terminal — it does not destroy postsynaptic nAChRs; the receptors remain intact and functional, which is why recovery occurs when new nerve sprouts establish synaptic contact; intravenous immunoglobulin is not the established first-line treatment for wound botulism.
Option D: Option D is incorrect because botulinum toxin does not alkylate or destroy AChE — AChE is an extracellular enzyme anchored in the basal lamina and is structurally unrelated to the intracellular SNARE proteins that botulinum toxin cleaves; recombinant AChE replacement is not an established treatment for botulism.
Option E: Option E is incorrect because neostigmine is not partially effective in botulinum toxin paralysis and should not be given empirically — its mechanism requires cleft ACh that is absent; and neostigmine has no known competitive inhibitory effect on the toxin's neuronal binding proteins.
10. A 24-year-old man sustained a complete C5 spinal cord injury in a motorcycle accident 6 weeks ago. He is admitted for elective percutaneous endoscopic gastrostomy tube placement under monitored anesthesia care. The anesthesiologist needs to secure the airway. A colleague suggests that succinylcholine is now safe because 6 weeks have passed since the acute injury and the patient has shown no signs of motor recovery. Which of the following is the most accurate assessment of succinylcholine safety at this time point?
A) Succinylcholine is now safe because extrajunctional nAChR upregulation peaks at 2 to 3 weeks post-injury and fully resolves within 4 to 6 weeks as the spinal cord stabilizes; at 6 weeks, extrajunctional receptor density has returned to normal and the hyperkalemia risk has passed
B) Succinylcholine is safe in this patient specifically because the injury is at the cervical spinal cord rather than at the level of the lower motor neuron; extrajunctional receptor upregulation requires direct peripheral nerve or muscle denervation — upper motor neuron injuries above C7 do not produce the muscle membrane changes needed for extrajunctional receptor proliferation
C) Succinylcholine is safe at 6 weeks because the absence of motor recovery indicates that the motor neurons below the level of injury remain viable but non-functional; viable but non-functional lower motor neurons continue to supply trophic support to muscle fibers, preventing extrajunctional receptor upregulation
D) Succinylcholine remains contraindicated at 6 weeks post-spinal cord injury — extrajunctional gamma-subunit nAChR upregulation persists for months after the triggering condition, not weeks; the absence of motor recovery does not indicate return of normal junctional receptor distribution, and succinylcholine administration at this time point carries a substantial risk of life-threatening hyperkalemia; rocuronium is the appropriate alternative
E) Succinylcholine is safe at 6 weeks because the serum potassium has been normal on recent laboratory testing; normal baseline serum potassium confirms that extrajunctional receptors are not generating resting potassium leak and indicates that the succinylcholine-triggered hyperkalemia risk has resolved
ANSWER: D
Rationale:
This question asked you to apply the time course and persistence of extrajunctional receptor upregulation to a patient 6 weeks after spinal cord injury and assess succinylcholine safety. Extrajunctional gamma-subunit nAChR upregulation begins within 24 to 48 hours of the triggering condition — denervation, burns, immobilization, or critical illness — and persists for months, not weeks. At 6 weeks post-injury, this patient's extrajunctional receptor proliferation is fully established and persisting across the muscle membrane surface. The absence of motor recovery does not indicate resolution of the receptor changes — in complete spinal cord injury, lower motor neuron trophic influence to the muscles below the level of injury is reduced or eliminated by the disruption of descending pathways and the secondary changes that follow, driving the same muscle membrane adaptations seen with direct denervation. Succinylcholine administration at 6 weeks would depolarize the vastly expanded extrajunctional receptor surface bearing gamma-subunit receptors with long open times — producing aggregate potassium efflux capable of raising serum potassium to life-threatening levels. The contraindication applies throughout the period of extrajunctional upregulation, which in complete spinal cord injury may be indefinite. Rocuronium is the appropriate alternative.
Option A: Option A is incorrect because extrajunctional upregulation does not resolve within 4 to 6 weeks — the stated resolution timeline is a common misconception; upregulation persists for months and may be permanent in complete neurological injuries where reinnervation never occurs.
Option B: Option B is incorrect because upper motor neuron injuries including spinal cord injury above the level of the lower motor neuron do drive extrajunctional receptor upregulation — the mechanism involves reduced lower motor neuron trophic influence, disuse atrophy, and muscle membrane remodeling that follows disruption of normal neural input regardless of whether the injury is at the upper or lower motor neuron level; both types of injury lead to extrajunctional proliferation.
Option C: Option C is incorrect because in complete spinal cord injury, the lower motor neurons below the level of injury may remain anatomically intact but their trophic influence on muscles is disrupted by the loss of normal neural activity and the secondary injury cascade; viable but electrically silent motor neurons do not prevent extrajunctional upregulation.
Option E: Option E is incorrect because normal baseline serum potassium does not indicate resolution of the extrajunctional receptor hyperkalemia risk — extrajunctional receptors are not constitutively active and do not produce resting potassium leak; they are only activated by agonists such as succinylcholine, and their presence cannot be inferred from baseline potassium levels.
11. A 63-year-old woman undergoes an elective right hemicolectomy under general anesthesia with cisatracurium for neuromuscular relaxation. At the end of the case, the anesthesiologist applies tactile TOF monitoring to the ulnar nerve and feels 4 twitches in response to stimulation. He administers neostigmine 0.04 mg/kg with glycopyrrolate and extubates the patient. In the post-anesthesia care unit, the patient has difficulty swallowing, desaturates to 88%, and aspirates. A colleague reviewing the case notes that no quantitative monitoring device was used. Which of the following most accurately explains why tactile confirmation of TOF count 4 was insufficient to confirm safe extubation in this patient?
A) Tactile TOF monitoring at the ulnar nerve is inherently unreliable because the adductor pollicis muscle is not accessible by touch; the correct technique requires visual observation of the thumb adduction, and tactile assessment through the glove consistently underestimates the degree of fade present
B) A TOF count of 4 confirms that four twitches are detectable but does not provide information about the ratio of the fourth twitch to the first — the TOF ratio may be well below 0.9 even when all four twitches are present; clinically significant residual neuromuscular blockade (TOF ratio below 0.9) causes measurable impairment of pharyngeal function and aspiration risk, and this degree of residual block cannot be reliably detected by tactile or visual subjective assessment of four twitches
C) Neostigmine at 0.04 mg/kg is an underdose — the correct reversal dose when TOF count is 4 is 0.07 mg/kg; the inadequate reversal dose left residual receptor occupancy by cisatracurium that would have been fully reversed by the correct dose, and the aspiration reflects pharmacological inadequacy rather than monitoring failure
D) The error was in the timing of extubation — the patient should have been maintained in the operating room for at least 30 minutes after neostigmine administration before extubation, because neostigmine takes 30 minutes to fully reverse cisatracurium block regardless of TOF count; the TOF count of 4 at the time of extubation was accurate but premature
E) Tactile assessment of TOF count 4 at the ulnar nerve accurately confirms a TOF ratio of approximately 0.9 in experienced hands; the adverse outcome in this patient reflects an underlying swallowing disorder unrelated to residual neuromuscular block, and the monitoring approach was appropriate given the available equipment
ANSWER: B
Rationale:
This question asked you to identify why TOF count 4 is insufficient as the sole criterion for safe extubation. The TOF count — the number of detectable twitches from zero to four — is a measure of block depth, not block completeness. When all four twitches are detectable (TOF count 4), the TOF ratio — the amplitude of the fourth twitch divided by the amplitude of the first — may still be substantially below 0.9. A TOF ratio below 0.9 by quantitative acceleromyography at the adductor pollicis is the evidence-based threshold for defining clinically significant residual neuromuscular blockade. At TOF ratios below 0.9, pharyngeal muscle dysfunction, impaired upper airway protective reflexes, reduced hypoxic ventilatory response, and increased aspiration risk have been documented. Critically, tactile and visual subjective assessment of TOF cannot reliably detect fade when the TOF ratio is between approximately 0.4 and 0.9 — which is precisely the range where clinically meaningful residual block is present. The patient in this scenario had four detectable twitches but likely had a TOF ratio in the 0.5 to 0.8 range — adequate to produce four palpable twitches but insufficient to protect the airway. Only quantitative acceleromyography at the adductor pollicis providing a confirmed numeric TOF ratio of 0.9 or greater is sufficient to confirm safe extubation.
Option A: Option A is incorrect because tactile assessment of thumb adduction through a glove can detect the presence or absence of twitches, and the monitoring site is appropriate — the error was interpreting count 4 as equivalent to adequate recovery, not the tactile assessment technique itself; visual versus tactile distinction does not explain the adverse outcome.
Option C: Option C is incorrect because neostigmine 0.04 mg/kg is within the standard dose range for reversal when block is at a moderate level with TOF count 4 — the stated underdose of 0.04 mg/kg compared to 0.07 mg/kg is not the established explanation for the adverse outcome; the fundamental error was monitoring inadequacy, not reversal dose selection.
Option D: Option D is incorrect because no fixed 30-minute waiting period after neostigmine is established as standard practice — the criterion for extubation is objective confirmation of adequate recovery by quantitative monitoring, not a time-based threshold; neostigmine's onset of action is 5 to 10 minutes and the reversal criterion is a confirmed TOF ratio, not elapsed time.
Option E: Option E is incorrect because tactile assessment of TOF count 4 does not accurately confirm a TOF ratio of approximately 0.9 — this is the well-established limitation of subjective monitoring that the evidence-based switch to quantitative monitoring is designed to address; attributing the adverse outcome to an unrelated swallowing disorder avoids the correct identification of monitoring failure as the root cause.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.